&nbsp;

Sep 2024

Drug

riTUXimab

Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™

Quick Link(s):

Jun 2025

Drug

romidepsin

Other Name(s): Istodax®

Quick Link(s):

Mar 2023

Drug

ramucirumab

Other Name(s): Cyramza®

Quick Link(s):

Mar 2023

Regimen

RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma

Drugs Used:

riTUXimab

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

RITU(MNT)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma

Drugs Used:

riTUXimab

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

RALT

Cancer Type:

Gastrointestinal,

Colorectal,

Esophagus,

Gastric / Stomach,

Small bowel and appendix

Intent: Adjuvant, Palliative

Funding:

New Drug Funding Program

Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer

New Drug Funding Program

Raltitrexed - Adjuvant Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Adjuvant Esophageal, Gastroesophageal Junction, or Gastric Cancer

Drugs Used:

raltitrexed

Quick Link(s):

Regimen Monograph

Jun 2024

Drug

radium-223

Other Name(s): Xofigo®

Quick Link(s):

Drug Monograph

Jun 2019

Drug

riTUXimab (subcut)

Other Name(s): Rituxan® SC

Quick Link(s):

Jun 2025

Regimen

RITU(MNT-SC)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma

Drugs Used:

riTUXimab (subcut)

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

XELOX+TRAS

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer

ODB - General Benefit

capecitabine

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

XELOX+NIVL

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab - First-line Treatment of Advanced Gastric, Esophageal, and Esophagogastric Junction Adenocarcinoma

ODB - General Benefit

capecitabine

Drugs Used: